title: Lord of the rings: a promising novel treatment for renal cell carcinoma?
authors.forename: Martin
authors.initials: M
authors.lastname: Johansson
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000494:pharmacology; D023102:Anoikis / Q000187:drug effects*; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D002448:Cell Adhesion / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D017292:Doxazosin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D051417:Focal Adhesion Kinase 1 / Q000378:metabolism*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D009154:Mutation; D009361:Neoplasm Invasiveness; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects*; D057705:Transendothelial and Transepithelial Migration / Q000187:drug effects; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000235:genetics
chemical_list: C525921:2-(4-(biphenyl-4-sulfonyl)-piperazin-1-yl)-6,7-dipropoxyquinazolin-4-yl-amine; D058668:Adrenergic alpha-1 Receptor Antagonists; D000970:Antineoplastic Agents; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D051417:Focal Adhesion Kinase 1; C496050:PTK2 protein, human; D051057:Proto-Oncogene Proteins c-akt; C497446:VHL protein, human; D017292:Doxazosin